Patents by Inventor Junxing Shi

Junxing Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES
    Publication number: 20100234585
    Abstract: The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Application
    Filed: May 25, 2010
    Publication date: September 16, 2010
    Applicant: Pharmasset, Inc.
    Inventors: Peiyuan Wang, Wojciech Stec, Byoung-Kwon Chun, Junxing Shi, Jinfa Du
  • 2?,3?-dideoxynucleoside analogues for the treatment or prevention of infections
    Patent number: 7772208
    Abstract: A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a ?-L- or ?-D-2?,3?-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: August 10, 2010
    Assignees: Pharmasset, Inc., Leland Stanford Junior University, Emory University
    Inventors: Raymond Schinazi, Robert Striker, Junxing Shi
  • 2-Fluoronucleosides
    Publication number: 20100173863
    Abstract: 2?-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2009
    Publication date: July 8, 2010
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
    Publication number: 20100168052
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: December 28, 2009
    Publication date: July 1, 2010
    Applicants: Pharmasset, Inc., EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Raymond F. Schinazi, Junxing Shi, Erik Gustafson, Joyce D. Fingeroth
  • PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES
    Publication number: 20100048917
    Abstract: The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Application
    Filed: September 3, 2009
    Publication date: February 25, 2010
    Applicant: Pharmassett, Inc.
    Inventors: Peiyuan Wang, Wojciech Stec, Byoung-Kwon Chun, Junxing Shi, Jinfa Du
  • 2?-fluoronucleosides
    Patent number: 7662938
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: February 16, 2010
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
    Patent number: 7638502
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: December 29, 2009
    Assignees: Pharmasset, Inc., Beth Israel Deaconess Medical Center, Emory University
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
    Patent number: 7601820
    Abstract: The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: October 13, 2009
    Assignee: Pharmasset, Inc.
    Inventors: Peiyuan Wang, Wojciech Stec, Byoung-Kwon Chun, Junxing Shi, Jinfa Du
  • N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS
    Publication number: 20090176730
    Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.4-acyl-2?,3?-didehydro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.
    Type: Application
    Filed: January 4, 2008
    Publication date: July 9, 2009
    Applicant: Pharmasset, Inc.
    Inventors: Michael J. Otto, Junxing Shi, Kyoichi A. Watanabe
  • 2'-FLUORONUCLEOSIDES
    Publication number: 20080300398
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Application
    Filed: November 19, 2007
    Publication date: December 4, 2008
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • 2', 3'-DIDEOXYNUCLEOSIDE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE INFECTIONS
    Publication number: 20080280846
    Abstract: A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a ?-L- or ?-D-2?,3?-dideoxynucleoside or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: January 8, 2008
    Publication date: November 13, 2008
    Applicants: Pharmasset, Inc., Emory University, Leland Stanford Junior University
    Inventors: Raymond F. Schinazi, Junxing Shi, Robert Striker
  • 2?-Fluoronucleosides
    Patent number: 7307065
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: December 11, 2007
    Assignees: Emory University, The University of Georgia Research Foundation, Inc.
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong
  • 2'-Fluoronucleoside phosphonates as antiviral agents
    Publication number: 20070225249
    Abstract: The present invention includes compounds and compositions of R-2?-fluoronucleoside phosphonates, as well as methods to treat HIV, HBV, HCV or abnormal cellular proliferation comprising administering said compounds or compositions.
    Type: Application
    Filed: March 22, 2007
    Publication date: September 27, 2007
    Inventor: Junxing Shi
  • Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
    Publication number: 20070197462
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: December 4, 2006
    Publication date: August 23, 2007
    Applicants: Pharmasset, Inc., Beth Israel Deaconess Medical Center, Emory University
    Inventors: Raymond Schinazi, Junxing Shi, Erik Gustafson, Joyce Fingeroth
  • Treatment of EBV and KHSV infection
    Patent number: 7211570
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 1, 2007
    Assignees: Pharmasset, Inc., Emory University, Beth Israel Deaconess Medical Center
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • N4-Acylcytosine Nucleosides for Treatment of Viral Infections
    Publication number: 20070078080
    Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2?,3?-dideoxy-5-fluorocytidine or N.sup.
    Type: Application
    Filed: July 31, 2006
    Publication date: April 5, 2007
    Inventors: Michael Otto, Junxing Shi, Kyoichi Watanabe
  • N-acylcytosine nucleosides for treatment of viral infections
    Patent number: 7105527
    Abstract: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acyl-2?,3?-dideoxy-5-fluorocytidine or N4-acyl-2?,3?-didehydro-2?,3?-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: September 12, 2006
    Inventors: Michael J. Otto, Junxing Shi, Kyoichi A. Watanabe
  • Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
    Publication number: 20060199783
    Abstract: The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to prepare the anti-HCV nucleosides containing the 2-deoxy-2-fluoro-2-C-methyl-o-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Application
    Filed: February 13, 2006
    Publication date: September 7, 2006
    Applicant: Pharmassett, Inc.
    Inventors: Peiyuan Wang, Wojciech Stec, Byoung-Kwon Chun, Junxing Shi, Jinfa Du
  • ?-2?- or 3?-halonucleosides
    Patent number: 6949522
    Abstract: The present invention includes compounds and compositions of ?-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: September 27, 2005
    Assignees: Pharmasset, Inc., The University of Georgia Research Foundation, Inc., Emory University
    Inventors: Michael J. Otto, Junxing Shi, Chung K. Chu, Raymond F. Schinazi, Giuseppe Gumina, Youhoon Chong, Yongseok Choi
  • 2?-fluoronucleosides
    Patent number: 6911424
    Abstract: A class of 2?-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: June 28, 2005
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Dennis C. Liotta, Chung K. Chu, J. Jeffrey McAtee, Junxing Shi, Yongseok Choi, Kyeong Lee, Joon H. Hong